Clinical Trial Update: Prospective Study on the Efficacy and Safety of 2 Week or 3 Week Xelox Regimen for Adjuvant Chemotherapy in CRC [Phase 1, Phase 2]

View source ↗

Summary

Prospective Phase 1/2 trial assessing the efficacy and safety of a 2-week or 3-week Xelox regimen as adjuvant chemotherapy for colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• XELOX (capecitabine + oxaliplatin)

Snippet

Sponsor: Zhejiang University | Conditions: Colorectal Cancer | Phase 1, Phase 2 | Status: COMPLETED